Maunoury, Franck <br/><br/>
Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.  [electronic resource] 

 -  PloS one  2018 
 - e0194329 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0194329  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amides<br/>Antiviral Agents--economics<br/>Benzofurans--economics<br/>Carbamates<br/>Cost-Benefit Analysis--methods<br/>Cyclopropanes<br/>Drug Therapy, Combination--economics<br/>Female<br/>France<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Imidazoles--economics<br/>Kidney Failure, Chronic--complications<br/>Liver Cirrhosis--complications<br/>Male<br/>Middle Aged<br/>Models, Economic<br/>Quality-Adjusted Life Years<br/>Quinoxalines--economics<br/>RNA, Viral--genetics<br/>Randomized Controlled Trials as Topic<br/>Renal Dialysis<br/>Sulfonamides